Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect

Clinical Neuropharmacology

Volumn 19, Issue 3, 1996, Pages 202-212

  Ahlskog, J Eric ^a   Wright, Kathy F ^a   Muenter, Manfred D ^b   Adler, Charles H ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

Cabergoline; Dopamine agonists; Ergolines; Parkinson's disease

Indexed keywords

CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; PLACEBO; SELEGILINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSKINESIA; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION;

EID: 0029940040     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619030-00002     Document Type: Article

References (9)

1. Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990;28:593-4.
2. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Adv Neurol 1990;53:539-43.
3. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/ carbidopa. Neurology 1993;43:1981-4.
4. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587-90.
5. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-16.
6. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist, cabergoline. Arch Neurol 1994;51:1236-41.
7. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-88.
8. Muenter MD, Tyce GM. L-Dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response and side effects. Mayo Clin Proc 1971;46:231-9.
9. Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1987:482-88.